Hana Pharm. Co., Ltd.
Financials
Valuation Metrics
Hana Pharm. Co., Ltd.'s Market Cap is ₩1468B. At end of 2025 it was ₩1994B. Ranked #1033 of 2,421 in KR market (top 43%), #508 of 781 on KOSPI (top 65%), #117 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 51%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 146.80B KRW | KR#1,033/2,421 Sec#117/231 |
| Revenue | 247.31B KRW | KR#921/2,421 Sec#51/231 |
| Net Income | 17.46B KRW | KR#753/2,421 Sec#50/231 |
| Total Assets | 446.69B KRW | KR#828/2,421 Sec#50/231 |
| Net Assets | 331.75B KRW | KR#682/2,421 Sec#45/231 |
| Employees | 730 | KR#347/2,421 Sec#29/231 |
| Value | ||
| P/E | 8.41x | KR#695/2,421 Sec#30/231 |
| P/B | 0.44x | KR#670/2,421 Sec#25/231 |
| P/S | 0.59x | KR#1,027/2,421 Sec#48/231 |
| EV/EBITDA | 7.03x | KR#385/2,421 Sec#13/231 |
| FCF Yield | 5.09% | KR#845/2,421 Sec#44/231 |
| Profitability | ||
| ROE | 5.26% | KR#1,071/2,421 Sec#73/231 |
| ROA | 3.91% | KR#895/2,421 Sec#72/231 |
| Op. Margin | 11.55% | KR#443/2,421 Sec#40/231 |
| Revenue Growth | 7.46% | KR#1,051/2,421 Sec#100/231 |
| Earnings Growth | -12.29% | KR#890/2,421 Sec#56/231 |
| Financial Health | ||
| Debt Ratio | 34.65% | KR#682/2,421 Sec#81/231 |
| Total Debt | 66.31B KRW | KR#894/2,421 Sec#61/231 |
| FCF | 7.47B KRW | KR#797/2,421 Sec#49/231 |
| Cash | 12.38B KRW | KR#1,561/2,421 Sec#128/231 |
| Current Ratio | 1.96x | KR#887/2,421 Sec#100/231 |
| Net Debt/EBITDA | 1.89x | KR#826/2,421 Sec#59/231 |
| Dividend | ||
| Div. Yield | 3.15% | KR#607/2,421 Sec#25/231 |
| Div. Growth | -49.02% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -32.35% | KR#1,631/2,421 Sec#130/231 |
| 1M Return | -1.08% | KR#1,357/2,421 Sec#102/231 |
| From 52W High | -33.33% | KR#651/2,421 Sec#40/231 |
| 1Y MDD | -33.03% | KR#339/2,421 Sec#27/231 |
| Trading | ||
| Volume | 16,017 shares | KR#1,696/2,421 Sec#166/231 |
| Trading Value | 132.6M KRW | KR#1,432/2,421 Sec#145/231 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/231 |
| Per Share | ||
| EPS | 983 KRW | KR#727/2,421 Sec#49/231 |
| BPS | 18,666 KRW | KR#563/2,421 Sec#37/231 |
Company Info
Established as Woocheon Pharmaceutical in 1973, this company changed its name to Hana Pharmaceutical in 1996 and was listed in 2018. It leads the market with strengths in narcotic analgesics and anesthetics, conducting specialty pharmaceutical businesses with over 380 health insurance-listed medicines. The company operates a manufacturing plant in Hwaseong, Gyeonggi-do, and an R&D center in Pangyo. It is expanding production through new injectable plant certification and focusing on developing biosimilars and DDS-based improved new drugs. Hana Pharmaceutical was founded in 1978 and is headquartered in Hwaseong-si, Gyeonggi-do.